Amended Current Report Filing (8-k/a)
May 18 2017 - 4:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
The Securities Exchange Act of 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 10, 2017
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
0-19731
|
|
94-3047598
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA
(Address of principal executive offices)
94404
(Zip Code)
(650) 574-3000
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFD 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
☐
|
Emerging growth company
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.
|
EXPLANATORY NOTE
This Current Report on Form 8-K/A (this Amendment) is being filed as an amendment to the Current Report on Form 8-K filed by Gilead
Sciences, Inc. (the Company) with the Securities and Exchange Commission on May 12, 2017 (the Original Filing). The Original Filing reported the final voting results of the Companys 2017 Annual Meeting of
Stockholders held on May 10, 2017 (the Annual Meeting). The sole purpose of this Amendment is to disclose the Companys decision as to the frequency with which executive compensation will be subject to future advisory
stockholder votes. No other changes have been made to the Original Filing other than to provide the disclosure set forth in this Amendment.
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
(d)
At the Annual Meeting, the
Companys stockholders voted, among other matters, on an advisory basis, as to the frequency with which executive compensation will be subject to future advisory stockholder votes. As previously reported in the Original Filing, the greatest
number of votes was cast in favor of every 1 Year.
In accordance with the Boards recommendation as set forth in the Companys
proxy statement for the Annual Meeting and consistent with the stated preference of the Companys stockholders, the Company has determined that future advisory stockholder votes on executive compensation will be conducted on an annual basis,
until the next advisory vote on this matter is held.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
GILEAD SCIENCES, INC.
|
(Registrant)
|
|
/s/ Brett A. Pletcher
|
Brett A. Pletcher
|
EVP, General Counsel and Corporate Secretary
|
Date: May 18, 2017
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024